Cargando…
Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate–Severe Crohn’s Disease
BACKGROUND: Crohn’s disease (CD) patients may benefit from biologic optimization. METHODS: We retrospectively assessed adverse events (AEs) and clinical/endoscopic response after ustekinumab re-induction in CD patients. RESULTS: We identified 28 patients, all with prior biologic exposure. Eight week...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802251/ https://www.ncbi.nlm.nih.gov/pubmed/36777048 http://dx.doi.org/10.1093/crocol/otac012 |